Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.
2.

DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.

Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP.

Gynecol Oncol. 2012 Oct;127(1):241-8. doi: 10.1016/j.ygyno.2012.06.017. Epub 2012 Jun 16.

3.

Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.

Dong L, Zhou Q, Zhang Z, Zhu Y, Duan T, Feng Y.

J Obstet Gynaecol Res. 2012 Aug;38(8):1077-85. doi: 10.1111/j.1447-0756.2011.01839.x. Epub 2012 Apr 30.

PMID:
22540333
4.

Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway.

Hanna RK, Zhou C, Malloy KM, Sun L, Zhong Y, Gehrig PA, Bae-Jump VL.

Gynecol Oncol. 2012 May;125(2):458-69. doi: 10.1016/j.ygyno.2012.01.009. Epub 2012 Jan 16.

5.

Metformin and cancer therapy.

Bost F, Sahra IB, Le Marchand-Brustel Y, Tanti JF.

Curr Opin Oncol. 2012 Jan;24(1):103-8. doi: 10.1097/CCO.0b013e32834d8155. Review.

PMID:
22123231
6.

p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy.

Attias-Geva Z, Bentov I, Kidron D, Amichay K, Sarfstein R, Fishman A, Bruchim I, Werner H.

Eur J Cancer. 2012 Jul;48(10):1570-80. doi: 10.1016/j.ejca.2011.09.014. Epub 2011 Oct 25.

PMID:
22033326
7.

Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer.

Werner H.

Oncogene. 2012 May 31;31(22):2703-14. doi: 10.1038/onc.2011.447. Epub 2011 Oct 3. Review.

PMID:
21963847
8.

The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.

Sarfstein R, Bruchim I, Fishman A, Werner H.

PLoS One. 2011;6(9):e24468. doi: 10.1371/journal.pone.0024468. Epub 2011 Sep 8.

9.

Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.

Rocha GZ, Dias MM, Ropelle ER, Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ, Carvalheira JB.

Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4.

10.

Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.

Attias-Geva Z, Bentov I, Ludwig DL, Fishman A, Bruchim I, Werner H.

Eur J Cancer. 2011 Jul;47(11):1717-26. doi: 10.1016/j.ejca.2011.02.019. Epub 2011 Mar 28.

PMID:
21450456
11.

Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.

Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP.

J Steroid Biochem Mol Biol. 2011 Sep;126(3-5):113-20. doi: 10.1016/j.jsbmb.2010.12.006. Epub 2010 Dec 17.

PMID:
21168492
12.

Health-related quality of life and mortality in a general and elderly population of patients with type 2 diabetes (ZODIAC-18).

Landman GW, van Hateren KJ, Kleefstra N, Groenier KH, Gans RO, Bilo HJ.

Diabetes Care. 2010 Nov;33(11):2378-82. doi: 10.2337/dc10-0979. Epub 2010 Aug 30.

13.

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.

Zakikhani M, Blouin MJ, Piura E, Pollak MN.

Breast Cancer Res Treat. 2010 Aug;123(1):271-9. doi: 10.1007/s10549-010-0763-9. Epub 2010 Feb 5.

PMID:
20135346
14.

Metformin reduces lipid accumulation in macrophages by inhibiting FOXO1-mediated transcription of fatty acid-binding protein 4.

Song J, Ren P, Zhang L, Wang XL, Chen L, Shen YH.

Biochem Biophys Res Commun. 2010 Feb 26;393(1):89-94. doi: 10.1016/j.bbrc.2010.01.086. Epub 2010 Jan 25.

PMID:
20102700
15.

AMPK-mediated GSK3beta inhibition by isoliquiritigenin contributes to protecting mitochondria against iron-catalyzed oxidative stress.

Choi SH, Kim YW, Kim SG.

Biochem Pharmacol. 2010 May 1;79(9):1352-62. doi: 10.1016/j.bcp.2009.12.011. Epub 2009 Dec 21.

PMID:
20026081
16.

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy.

Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL.

Gynecol Oncol. 2010 Jan;116(1):92-8. doi: 10.1016/j.ygyno.2009.09.024. Epub 2009 Oct 12.

17.

For debate: the pathophysiological significance of IGF-I receptor overexpression: new insights.

Werner H.

Pediatr Endocrinol Rev. 2009 Sep;7(1):2-5. Review. No abstract available.

PMID:
19696710
18.

Targeting the IGF1 axis in cancer proliferation.

Bruchim I, Attias Z, Werner H.

Expert Opin Ther Targets. 2009 Oct;13(10):1179-92. doi: 10.1517/14728220903201702. Review.

PMID:
19663648
19.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Currie CJ, Poole CD, Gale EA.

Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2.

PMID:
19572116
20.

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes.

Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM.

Diabetes Care. 2009 Sep;32(9):1620-5. doi: 10.2337/dc08-2175. Epub 2009 Jun 29.

Supplemental Content

Support Center